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Abstract
Objectives Despite recent advances in the treatment of metastatic prostate
cancer, survival rates are low and treatment options are limited to chemotherapy
and hormonal therapy. 131I-MIP-1095 is a recently developed prostate-specific
membrane antigen (PSMA)-targeting, small molecular weight radiopharmaceuti-
cal which has anti-tumour activity as a single agent. Our purpose was to deter-
mine in vitro the potential benefit to be gained by combining 131I-MIP-1095 with
cytotoxic drug treatments.
Methods Various cytotoxic agents were evaluated in combination with
131I-MIP-1095 for their capacity to delay the growth of LNCaP cells cultured as
multicellular tumour spheroids. Two end-points were used to assess treatment
efficacy: (i) the time required for doubling of spheroid volume and (ii) the area
under the volume–time growth curves.
Key findings The PARP-1 inhibitor olaparib, the topoisomerase I inhibitor
topotecan, the proteasome inhibitor bortezomib, the inhibitor of the P53–
MDM2 interaction nutlin-3 and the copper-chelated form of the oxidising agent
disulfiram (DSF:Cu) all significantly enhanced the inhibition of the growth of
spheroids induced by 131I-MIP-1095. However, the Chk1 inhibitor AZD7762
failed to potentiate the effect of 131I-MIP-1095.
Conclusions These results indicate that targeted radiotherapy of prostate cancer
may be optimised by combining its administration with chemotherapy.
Introduction
The prognosis is favourable for prostatic carcinoma (PCa),
which is restricted to the site of origin, whereas there is no
cure for the disseminated disease.[1,2] While external beam
radiotherapy may be effective for local control and pallia-
tion, its use to treat widespread disease is limited.[3] Fur-
thermore, intense local irradiation can result in significant
undesirable damage to adjacent, non-cancerous tissues, and
wide-field radiotherapy is associated with severe bone
marrow toxicity. Targeted radiotherapy seeks to overcome
the obstacles to cure imposed by metastatic dissemination
and the intolerance of normal tissue to ionising radiation.
Radiolabelled peptides based upon the glutamate–urea–
lysine structure have been developed. These bind to pros-
tate-specific membrane antigen (PSMA) and exhibit high
uptake and prolonged retention selectively in prostatic car-
cinoma cells and in experimental tumours.[4,5] PSMA is
expressed by almost all PCa, particularly in poorly differen-
tiated, metastatic and hormone-refractory disease.[6-8]
The PSMA-affinic agent, 124I-MIP-1095, detected meta-
static PCa lesions in soft tissues and bone,[9,10] and recent
results of the first therapeutic use of this compound
labelled with iodine-131 (131I) reported a reduction in bone
pain and improved quality of life.[11] It was also demon-
strated that 131I-MIP-1095 did not cause immediate kidney
dysfunction despite high renal uptake; only, mild and
reversible haematological toxicities and xerostomia were
reported.[11] However, maximal therapeutic potency of tar-
geted radiotherapy will be derived from its combination
with radiosensitisers.[12] Several studies have been con-
ducted of radiosensitising agents in combination with
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external beam radiation. In contrast, the evaluation of
drugs for the optimisation of radionuclide therapy has
received relatively little scrutiny. To enhance targeted
radiotherapy, there are several options for intervention,
namely the DNA repair pathways, redox homoeostasis
and pathways associated with pro- and anti-tumour cell
survival.[13] The primary aim of this study was to determine
the potential enhancement of targeted radiotherapy using
131I-MIP-1095 by means of combination with radiosensitis-
ers (Table 1).
Evaluation of the anti-tumour potency of DSF:Cu, nut-
lin-3, olaparib, topotecan, bortezomib and AZD7762 in
combination with 131I-MIP-1095 was carried out using
multicellular tumour spheroids derived from the LNCaP
prostate carcinoma cell line. Spheroids are representative of
micrometastases in their prevascular stage of development.
Radiopharmaceuticals exert their cytotoxic effect by direct
deposition of energy in targeted cells and by cross-fire to
neighbouring cells. In monolayers which have accumulated
radionuclides, most of the decay particle energy is depos-
ited above and below the plane of the cultured cells. In con-
trast, spheroids absorb a greater proportion of cross-fire
radiation. Accordingly, spheroids constitute an appropriate
model to study the therapeutic efficacy of radiopharmaceu-
ticals. Moreover, these cellular aggregates are similar to the
size class of malignant disease which is optimally sensitive
to treatment with targeted radionuclides.[14] Our findings
indicate the therapeutic potential of 131I-MIP-1095 used in
combination with radiosensitisers, a novel approach to the
management of metastatic PCa.
Materials and Methods
Cell culture, drugs and solvents
The LNCaP prostate carcinoma cell line (ATCC, Middlesex,
UK) was selected for its ability to internalise 131I-MIP-1095
and to grow spheroids. LNCaP cells were maintained in
Roswell Park Memorial Institute medium supplemented
with 10% (v/v) hyclone foetal calf serum (Fisher Scientific,
Loughborough, UK), 4 mM L-glutamine, 10 mM HEPES,
2.52 g/l D-glucose and 1 mM sodium pyruvate. Unless
otherwise stated, all reagents used for cell culture were pur-
chased from Life Technologies (Paisley, UK). DSF, Cu and
topotecan were purchased from Sigma-Aldrich (Dorset,
UK). Nutlin-3 was purchased from Biotechne—R&D sys-
tems (Oxon, UK). Olaparib, bortezomib and AZD7762
were purchased from Stratech Scientific Ltd (Suffolk, UK).
Only, topotecan and Cu were dissolved in aqueous solu-
tions. DSF, nutlin-3, olaparib, bortezomib and AZD7762
were dissolved in dimethyl sulfoxide (DMSO). The concen-
tration of DMSO used for the treatment of spheroids was
0.1% (v/v). Stock solutions of drugs were prepared at 1000
times the required concentration.
Cell cycle
LNCaP monolayers were exposed to 1 lM AZD7762 and
immediately irradiated with 5 Gy using an RS225 irradiator
(Xstrahl, Surrey, UK) at a dose rate of 1.64 Gy/min. After
12 h, the cells were harvested by trypsinisation and fixed in
70% ethanol at 20 °C. LNCaP cells were stained with
20 lg/ml propidium iodide and 4 lg/ml RNAse A for at
least 10 min prior to analysis using FACSCalibur (BD Bio-
sciences, Mountain View, CA), as described previously.[15]
Spheroid initiation
LNCaP spheroids were obtained using the liquid overlay
technique.[16] The monolayers were trypsinised and
reseeded at a cellular density of 120 000 cells/cm2 into 1%
(w/v) agar-coated flasks. After 3–4 days incubation, spher-
oids had formed.
Immunohistochemistry
Hypoxia was detected using the hypoxyprobeTM kit (Hypox-
yprobe Inc, Burlington, MA, USA). Live spheroids were
treated for 24 h with 200 lM pimonidazole in culture med-
ium prior processing. The spheroid sections were de-waxed
in xylene and re-hydrated by successive immersions in
graded alcohol and distilled water. Endogenous peroxidase
Table 1 The mechanism of action of the radiosensitisers
Drug Mechanism of action of radiosensitisation Target
DSF:Cu Oxidative stress generation [43] Cellular thiols, SOD, NF-jB
Nutlin- p53-mediated apoptosis[44] MDM2
Olaparib Inhibition of DNA damage repair[45,46] PARP-1
Topotecan Generation of double-stranded DNA breaks[47,48] Topoisomerase I
Bortezomib Inhibition of NF-kB activation,[49] oxidative stress generation,[50] downregulation of the
DNA damage response[51]
26S proteasome
AZD7762 Inhibition of G2 arrest
[35,52] Chk1
SOD, superoxide dismutase; NF-jB, nuclear factor jB; MDM2, mouse double minute 2; PARP-1, poly(ADP-ribose) polymerase 1; Chk1, checkpoint
kinase 1.
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activity was quenched by incubation in 0.3% (v/v) H2O2
solution in methanol for 30 min. For Ki-67 staining only,
heat-induced antigen retrieval was performed in a 10 mM
sodium citrate, 0.05% (v/v) Tween-20, pH6 buffer at 98 °C
for 25 min. The sections were then washed using
Tris-buffered Tween before being exposed to anti-Ki67
(ThermoFisher Scientific, Hemel Hempstead, UK, 1 : 100),
anti-PSMA (DAKO, Cambridge, UK, 1 : 500) or anti-
pimonidazole adducts (Hypoxyprobe, Inc, Burlington, MA,
1 : 5000) antibodies. For pimonidazole and PSMA staining,
the secondary antibody was the rabbit biotinylated poly-
clonal anti-mouse antibody (DAKO, Cambridge, UK,
1 : 100). For Ki67 staining, the anti-rabbit EnVisionTM sys-
tem (DAKO, Cambridge, UK) was used in conjunction
with the 3, 30-diaminobenzidine (DAB) substrate kit for
peroxidase (Vector Laboratories, Burlingame, CA). Spher-
oid sections were counterstained with haematoxylin and
immersed in Scott’s tap water. The haematoxylin and eosin
(H&E) staining procedure involved successive immersions
of spheroid sections in haematoxylin, 1% (v/v) acid alco-
hol, Scott’s tap water and eosin with intermediate washes in
water. Finally, the sections were dehydrated and rewaxed by
successive immersions in graded alcohol and xylene before
mounting on a glass coverslip.
131I-MIP-1095 radiolabelling
131I-MIP-1095 was synthesised as described previously.[5]
Briefly, radiolabelling was accomplished by iododestannyla-
tion of the trimethylstannyl precursor with 1.85–3.7 GBq
of sodium iodide-131 using acidic oxidising conditions to
form 131I-MIP-1095 in moderate radiochemical yield (50–
70%). The radioiododestannylation afforded the 131I-
labelled tri-tert-butyl esters that were purified using C18
Sep Pak columns and deprotected with trifluoroacetic acid
to afford the desired radioiodinated compound in >95%
radiochemical purity. The specific activity was determined
to be ≥ 148 GBq/lmol.
131I-MIP-1095 uptake assay
LNCaP spheroids were incubated for a range of times in
culture medium containing 0.37 MBq/ml 131I-MIP-1095.
LNCaP spheroids were then washed three times in culture
medium. The radioactivity retained in the spheroids was
measured using a c-counter (Canberra Packard, Berkshire,
UK). Protein extracts of spheroids were obtained by incu-
bation in 100 ll lysis buffer (protease inhibitor (Cal-
biochem), 1.19 g HEPES, 1.46 g NaCl and 0.5 ml Nonidet
P-40 in 100 ml distilled water, pH 7) for 45 min on ice.
Protein concentration was determined using the Bradford
assay.[17] Radiopharmaceutical uptake was expressed as
counts per minute (CPM) per mg of protein.
Treatment of spheroids and growth curve
analysis
LNCaP spheroids were treated with 131I-MIP-1095 for 2 h
in the presence or absence of various radiosensitisers.
Thereafter, excess 131I-MIP-1095 was removed by washing.
The spheroids were re-incubated for 22 h in the presence
of radiosensitisers before their removal by washing. Then,
spheroids of approximately 100 lm in diameter were man-
ually selected and individually transferred into agar-coated
wells. Two orthogonal diameters, dmax and dmin (lm),
were measured using the image analysis software
ImageJ, and the volume, V (106 lm3), was calculated using:
V = p 9 dmax 9 dmin²/6 000 000.
[18] To enable compar-
ison between treatments, the volume, V, of a single spher-
oid was divided by its initial volume V0 (V/V0). Linear
regression analysis of the relationship between the loga-
rithm of the V/V0 value and time t was performed using
the method of least squares. The linear regression equa-
tion was fitted to the exponential part of the spheroid
growth curve. The slope, b, and the y-intercept, a, of the
linear regression equation logV/V0 = bt + a were used to
calculate the time, s2, required for a two-fold increase in
spheroid volume from day 0: s2 = (log2a)/b. To evaluate
the effect of combination treatment over the whole course
of the experiment, the area under the logV/V0 vs time curve
(AUC) was also calculated for individual spheroids using
trapezoidal approximation.
Statistical analysis
Statistical analyses were carried out using the software SPSS
v.19 (IBM, New York, NY, USA). The distributions of s2
and AUC values were not normal, as indicated by the
Shapiro–Wilk test. Therefore, nonparametric Kruskal–Wal-
lis testing was used to determine whether experimental data
indicated a significant level of difference between the medi-
ans of the groups. If the P-value of the Kruskal–Wallis test
was <0.05, the Mann–Whitney test was used for pairwise
comparisons. Firstly, to demonstrate enhancement of radi-
ation-induced spheroid growth delay by radiosensitisers,
the observed effect in response to a combination treatment
of a radiosensitiser with 131I-MIP-1095 had to be concomi-
tantly greater than that induced by 131I-MIP-1095 alone
and than that induced by the radiosensitiser alone.
Secondly, an absence of enhancement of 131I-MIP-1095-
induced growth delay could be due to insufficient radiosen-
sitiser dosage. Therefore, the evaluation of the modification
of the effect of 131I-MIP-1095 involved a family of four
pairwise comparisons: radiosensitiser vs untreated control,
131I-MIP-1095 vs untreated control, radiosensitiser +
131I-MIP-1095 vs radiosensitiser and radiosensitiser +
131I-MIP-1095 vs 131I-MIP-1095. To compensate for multi-
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ple pairwise comparisons, Bonferroni correction was
applied. To retain the criterion P < 0.05, the level of signifi-
cance of each pairwise comparison was set to 0.0125.
Results
Morphological characterisation of LNCaP
spheroids
The effect of size on the internal morphology of
LNCaP spheroids was analysed. H&E staining revealed a
size-dependent change in LNCaP spheroid internal struc-
ture (Figure 1). LNCaP spheroids of approximately
100 lm diameter were oxygenated and contained Ki-67-
positive, proliferating cells homogeneously distributed
throughout the section (Figure 1). In contrast, mature
LNCaP spheroids of approximately 500 lm in diameter
contained a hypoxic core surrounded by an outer layer of
Ki-67-positive proliferating cells (Figure 1). In both spher-
oids of 100 and 500 lm in diameter, PSMA expression was
homogeneous throughout the sections, regardless of inter-
nal morphology (Figure 1). LNCaP spheroids, as models of
H&EKi-67
D
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Figure 1 The effect of size on internal LNCaP spheroid morphology. The markers of hypoxia (pimonidazole adducts), proliferation (Ki-67) and
histological organisation (haematoxylin and eosin, H&E) as well as PSMA were detected by immunohistochemistry in LNCaP spheroid sections 0
and 21 days following initiation. The bars indicate 150 lm.
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Figure 2 The time dependency of 131I-MIP-1095 binding to LNCaP spheroids. (a) The effect of temperature on uptake following treatment with
0.37 MBq/ml 131I-MIP-1095 for 2 h. Independent t-test: **P < 0.01. (b) The binding kinetic of 0.37 MBq/ml 131I-MIP-1095 to LNCaP spheroids
was evaluated at 4 °C. (c) The growth of LNCaP spheroids following treatment with 131I-MIP-1095 was evaluated. The s2 and AUC values were
calculated to quantify spheroids growth delay according to material and methods. The medians of s2 and AUC values of the groups treated with
131I-MIP-1095 alone were statistically compared with that of the untreated controls (*). Data are mean  SEM (n = 3), ***P < 0.001.
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avascular micrometastasis and of approximately 100 lm
diameter, were selected for the investigation of 131I-MIP-
1095 uptake and growth delay.
Characterisation of the spheroid growth
delay induced by 131I-MIP-1095
The temperature-dependent and PSMA-specific internali-
sation of 131I-MIP-1095 by LNCaP cells grown as monolay-
ers is an endocytotic process.[4] At 4 °C, the association of
131I-MIP-1095 with spheroids was 25% of that obtained at
37 °C (P < 0.01) (Figure 2a). The uptake observed at 4 °C
represents the fraction of 131I-MIP-1095 bound to PSMA,
whereas cellular accumulation at 37 °C is the sum of
binding and internalisation of radiopharmaceutical. This
apportionment of activity in spheroids is similar to that
previously observed in cellular monolayers.[4] Saturation of
binding of 131I-MIP-1095 to PSMA at 4 °C was achieved
after 2 h (Figure 2b).
Based on the uptake data, the effect of 131I-MIP-1095
treatment for 2 h on the growth of LNCaP spheroids was
evaluated as a single agent in order to determine the
radioactive concentration to be used in combination with
radiosensitisers (Figure 2c). There was a significant modi-
fication of s2 and AUC values in response to treatment
with 131I-MIP-1095. For instance, the AUC values
decreased from 25.75  0.84 to 20.89  0.81, 20.09 
0.56 or 19.30  0.61 in response to treatment with
0, 0.37, 1 or 10 MBq/ml 131I-MIP-1095. Correspondingly,
s2 values increased from 2.94  0.21 to 4.28  0.21,
4.03  0.18 or 4.37  0.22 days in response to treatment
with 0, 0.37, 1 or 10 MBq/ml 131I-MIP-1095 (Figure 2c).
Based on these results, a radioactivity concentration of
0.37 MBq/ml 131I-MIP-1095 was selected for the assess-
ment of the modulation of radiopharmaceutical-induced
growth delay.
Table 2 Comparison between plasma concentrations and in vitro
radiosensitising concentrations of the drugs
Drug Radiosensitising concentration Plasma concentration
DSF:Cu 1 lM 1 lM[19]
Topotecan 10 nM 7.21–17.03 nM[20]
24.8–108.9 nM[25]
Olaparib 1 lM 0.23–2.3 lM[24]
5.75 lM[23]
11 lM[24]
Bortezomib 10 nM 580 nM[21]
205.60 nM[22]
14.53 0.65***5.62 0.24***0.37 MBq/ml
24.41 0.982.82 0.15Control
AUC
0.87 1.02†††¶¶¶13.85 2.41†††¶¶¶1 μM DSF:Cu + 0.37 MBq/ml
20.87 1.494.13 0.461 μM DSF:Cu
Treatment τ2
0 21147
225
180
135
90
45
0
V
/V
0
Time (days)
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1 µM DSF:Cu 
0.37 MBq/ml
1 µM DSF:Cu
+ 0.37 MBq/ml
Figure 3 The effect of DSF:Cu on the growth delay induced by
131I-MIP-1095 in LNCaP spheroids. The effect of DSF:Cu on the
growth delay induced by 0.37 MBq/ml 131I-MIP-1095 was evaluated
in LNCaP spheroids. The medians of s2 and AUC values of the spher-
oids exposed to the single agent treatments were statistically com-
pared with that of the untreated controls (*). The medians of s2 and
AUC values of the spheroids treated with a combination of 131I-MIP-
1095 with DSF:Cu were compared with those of the spheroids treated
with 131I-MIP-1095 alone (¶) and to those of the spheroids treated
with DSF:Cu alone (†). Data are mean  SEM (n = 3), and three
symbols indicate P < 0.001.
–3.25 0.75†††¶¶¶N/A10 μM nutlin-3 + 0.37 MBq/ml
12.86 0.44***6.20 0.20***0.37 MBq/ml
19.20 1.20***4.35 0.25***10 μM nutlin-3
24.49 1.142.99 0.18Control
AUC
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10 µM nutlin-3
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+ 0.37 MBq/ml 
Figure 4 The effect of nutlin-3 on the growth delay induced by
131I-MIP-1095 in LNCaP spheroids. The effect of nutlin-3 on the
growth delay induced by 0.37 MBq/ml 131I-MIP-1095 was evaluated
in LNCaP spheroids. The medians of s2 and AUC values of the spher-
oids exposed to the single agent treatments were statistically
compared with that of the untreated controls (*). The medians of s2
and AUC values of the spheroids treated with a combination of
131I-MIP-1095 with nutlin-3 were compared with those of the
spheroids treated with 131I-MIP-1095 alone (¶) and to those of the
spheroids treated with nutlin-3 alone (†). Data are mean  SEM
(n = 3), and three symbols indicate P < 0.001.
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Evaluation of the potential enhancement of
the spheroid growth delay induced by 131I-
MIP-1095 by combination with
radiosensitisers
The selection of radiosensitising concentrations of drugs
was based on previously published data derived from
experimentation in vitro as well as plasma concentrations
achieved in clinical trials (Table 2).
The enhancement of 131I-MIP-1095 spheroid growth
delay by DSF:Cu was demonstrated by the statistically sig-
nificant modulation of s2 and AUC values (Figure 3). For
instance, the AUC values were 14.53  0.65 (P < 0.001),
20.87  1.49 and 0.87  1.02 (P < 0.001) for spheroids
treated with 0.37 MBq/ml 131I-MIP-1095 alone, 1 lM DSF:
Cu alone and the combination of both agents, respectively.
The analogous s2 values were 5.62  0.24 (P < 0.001),
4.13  0.46 and 13.85  2.41 (P < 0.001) days for
spheroids treated with 0.37 MBq/ml 131I-MIP-1095 alone,
1 lM DSF:Cu alone and the combination of both agents,
respectively (Figure 3).
Similarly, the enhancements of 131I-MIP-1095 spheroid
growth delay by 10 lM nutlin-3 (Figure 4), 1 lM olaparib
(Figure 5), 0.1 lM topotecan (Figure 6) and 10 nM borte-
zomib (Figure 7) were indicated by the statistically signifi-
cant modulation of s2 and AUC values. For nutlin-3, the
determination of s2 values was impossible because the
spheroids exposed to the combination treatment did not
double in size (Figure 4).
Treatment with 1 lM AZD7762 as a single agent did not
result in spheroid growth delay nor did it enhance the
spheroid growth delay induced by 131I-MIP-1095
(Figure 8). For instance, the AUC values were 8.40  0.95
(P < 0.001), 17.90  0.62 and 8.86  0.93 following treat-
ment with 0.37 MBq/ml 131I-MIP-1095 alone, 1 lM
AZD7762 alone and the combination of both agents, respec-
tively. Similarly, the s2 values were 6.21  0.55 (P < 0.001),
3.20  0.19 and 6.58  0.67 following treatment with
0.37 MBq/ml 131I-MIP-1095 alone, 1 lM AZD7762 alone
and the combination of both agents, respectively (Figure 8).
Furthermore, treatment with 1 lM AZD7762 prevented the
accumulation of LNCaP cells in G2 following c-radiation
treatment (Figure 9). The proportions of LNCaP cells in G2
were 14.67%  0.98, 25.90%  2.46, 16.00%  0.93 and
13.30%  0.51 for the untreated group and those treated
4.95 0.55†††¶¶¶11.55 0.95†††¶¶¶1 μM olaparib + 0.37 MBq/ml
19.51 0.553.01 0.161 μM olaparib
9.61 0.65***6.30 0.32***0.37 MBq/ml
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Figure 5 The effect of olaparib on the growth delay induced by
131I-MIP-1095 in LNCaP spheroids. The effect of olaparib on the
growth delay induced by 0.37 MBq/ml 131I-MIP-1095 was evaluated
in LNCaP spheroids. The medians of s2 and AUC values of the spher-
oids exposed to the single agent treatments were statistically com-
pared with that of the untreated controls (*). The medians of s2 and
AUC values of the spheroids treated with a combination of 131I-MIP-
1095 with olaparib were compared with those of the spheroids trea-
ted with 131I-MIP-1095 alone (¶) and to those of the spheroids treated
with olaparib alone (†). Data are mean  SEM (n = 3), and three
symbols indicate P < 0.001.
7.75 0.55†††¶¶7.94 0.61†††¶¶¶0.1 μM topotecan + 0.37 MBq/ml
17.58 0.543.25 0.160.1 μM topotecan
10.95 0.78***5.51 0.42***0.37 MBq/ml
18.64 0.493.06 0.15Control
AUC
0 21147
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0.1 µM topotecan
0.1 µM topotecan
0.37 MBq/ml
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Figure 6 The effect of topotecan on the growth delay induced by
131I-MIP-1095 in LNCaP spheroids. The effect of topotecan on the
growth delay induced by 0.37 MBq/ml 131I-MIP-1095 was evaluated
in LNCaP spheroids. The medians of s2 and AUC values of the spher-
oids exposed to the single agent treatments were statistically com-
pared with that of the untreated controls (*). The medians of s2 and
AUC values of the spheroids treated with a combination of 131I-MIP-
1095 with topotecan were compared with those of the spheroids
treated with 131I-MIP-1095 alone (¶) and to those of the spheroids
treated with topotecan alone (†). Data are mean  SEM (n = 3), two
symbols indicate P < 0.01, and three symbols indicate P < 0.001.
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with 5 Gy, 1 lM AZD7762 and the combination of both
agents, respectively. This result suggested that the lack of
sensitisation to 131I-MIP-1095 cannot be attributed to a
subeffective dosage of AZD7762.
Discussion
Our purpose was to evaluate the potency of radiosensitis-
ers, with various mechanisms of action, in combination
with the PSMA-specific radiopharmaceutical 131I-MIP-
1095. Modulators of the DNA damage response are repre-
sented by nutlin-3, which induces p53-mediated apoptosis,
olaparib, which inhibits DNA repair and the G2 arrest inhi-
bitor AZD7762. The oxidative agent DSF:Cu, the DNA
replication poison topotecan and the proteasome inhibitor
bortezomib were also assessed. A comparison of the
radiosensitising potency of drugs which possess a variety of
biological actions—for example DNA repair inhibitors vs
cell cycle regulation inhibitor vs ROS generators—is not
meaningful in the absence of knowledge of the cancer
phenotype of the target population. For instance, G2 arrest
inhibitors are most appropriate for the treatment of p53/
cancer types with efficient DNA repair capacity, whereas
the administration of nutlin-3 may be more suitable for the
management of p53+/+ cancer types. Furthermore, a com-
parison of the radiosensitising effectiveness of drugs is only
possible at equipotent concentrations of radiosensitisers as
single agents, that is at concentrations which inhibit the
target to the same extent.
Drugs which counteract stress responses such as DNA
damage repair inhibitors or modifiers of the cell cycle
response to radiation treatment are especially attractive for
use in combination with targeted radiopharmaceuticals as
the absence of a cytotoxic effect as a single agent would
spare non-malignant tissues which do not accumulate
tumour-targeted radiopharmaceutical. Therefore, the
choice of a radiosensitiser depends on the radiosensitising
potential, the phenotype of the cancer and on the toxicity
profile. Furthermore, it is important that the drug concen-
trations shown to enhance the growth delay induced by
131I-MIP-1095 are clinically relevant. It has been shown
that the radiosensitising concentrations of DSF:Cu, ola-
parib, topotecan and bortezomib described in this report
are achievable in the plasma of patients (Table 2).[19–26]
Currently, there is no phase I or II clinical trials involving
nutlin-3.[27,28]
8.01 0.69†††¶¶¶7.97 0.49†††¶¶¶10 nM bortezomib + 0.37 MBq/ml
13.89 0.45***5.08 0.21***0.37 MBq/ml
16.08 0.54***4.58 0.22***10 nM bortezomib
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Figure 7 The effect of bortezomib on the growth delay induced by
131I-MIP-1095 in LNCaP spheroids. The effect of bortezomib on the
growth delay induced by 0.37 MBq/ml 131I-MIP-1095 was evaluated
in LNCaP spheroids. The medians of s2 and AUC values of the spher-
oids exposed to the single agent treatments were statistically com-
pared with that of the untreated controls (*). The medians of s2 and
AUC values of the spheroids treated with a combination of 131I-MIP-
1095 with bortezomib were compared with those of the spheroids
treated with 131I-MIP-1095 alone (¶) and to those of the spheroids
treated with bortezomib alone (†). Data are mean  SEM (n = 3),
three symbols indicate P < 0.001.
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Figure 8 The effect of AZD7762 on the growth delay induced by
131I-MIP-1095 in LNCaP spheroids. The effect of AZD7762 on the
growth delay induced by 0.37 MBq/ml 131I-MIP-1095 was evaluated
in LNCaP spheroids. The medians of s2 and AUC values of the spher-
oids exposed to the single agent treatments were statistically com-
pared with that of the untreated controls (*). The medians of s2 and
AUC values of the spheroids treated with a combination of 131I-MIP-
1095 with AZD7762 were compared with those of the spheroids trea-
ted with 131I-MIP-1095 alone (¶) and to those of the spheroids treated
with AZD7762 alone (†). Data are mean  SEM (n = 3), three sym-
bols indicate P < 0.001.
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While it is expected that the most significant influence of
treatment with radiosensitisers will be potentiation of the
damage inflicted by decay particle bombardment of suscep-
tible cellular elements, it is noteworthy that enhancement
of therapeutic efficacy of radiopharmaceutical may also
result from increased cellular uptake. Indeed, pretreatment
with topotecan,[29] cisplatin[30] or doxorubicin[30] has been
reported to enhance the accumulation of tumour-targeted
radiopharmaceuticals. However, in the foregoing studies,
prior incubation for 24–48 h was required for enhance-
ment of cellular uptake, whereas no corresponding pre-
treatment was applied in the current study. Therefore,
simultaneous exposure to 131I-MIP-1095 and cytotoxic
drugs is unlikely to have resulted in increased intracellular
concentration, suggesting that radiosensitisation may be
the sole mechanism modulating 131I-MIP-1095-induced
inhibition of spheroid growth. However, the evaluation of
alternative schedules of delivery of 131I-MIP-1095 and
radiosensitisers is required to derive maximal therapeutic
efficacy.
We observed that the PARP-1 inhibitor olaparib potenti-
ated the LNCaP spheroid growth delay induced by 131I-
MIP-1095. Significantly, targeted radiotherapy is delivered
at a markedly lower dose rate than external beam
radiation.[31] Moreover, it has been shown that PARP
inhibitors are especially effective in the enhancement
of radiation kill at low doses.[32] Therefore, PARP
inhibitors may be appropriate for combination with
targeted radiopharmaceuticals characterised by a low
dose-rate radiation.
We report no enhancement of 131I-MIP-1095-induced
spheroid growth delay by the Chk1 inhibitor AZD7762.
This may be due to LNCaP cells harbouring a functional
p53 pathway,[33,34] which is known to limit the radiosen-
sitising potential of G2 arrest inhibitors such as
AZD7762.[35] Furthermore, it has been suggested that the
radiosensitivity of LNCaP cells may be due to inefficient
DNA damage repair in G2 phase.
[36] Therefore, the
observed decrease in the duration of G2 arrest induced by
AZD7762 following irradiation, which results in a reduc-
tion of the extent of DNA damage repair, may be of no
consequence. These observations highlight the importance
of the knowledge of the genotypic characteristics of
tumours, for the selection of radiosensitiser–radiophar-
maceutical combinations.
Spheroids which grow to a diameter of approximately
300 lm develop a non-proliferative, hypoxic core sur-
rounded by a proliferative layer of cells.[37] These fea-
tures of spheroids in an advanced stage of growth
confer resistance to therapy.[38–40] The current study of
the modulation of growth delay induced by 131I-MIP-
1095 was conducted using spheroids of 100 lm diameter
which had not yet undergone internal morphological
changes. In agreement with previous reports,[41,42] we
observed that PSMA expression was homogeneous in
small spheroids. However, larger spheroids of 500 lm in
diameter were also characterised by uniform expression
of PSMA. It is recommended that the current study
should be developed to address the potentiating effect of
the cytotoxic drugs on the growth delay induced by
131I-MIP-1095 in spheroids which have developed a
hypoxic core surrounded by proliferating region of cells.
Such analyses should evaluate the ability of combina-
tions of therapeutic modalities to overcome the antici-
pated resistance to treatment conferred by non-
proliferative and hypoxic regions.
Conclusions
Our preliminary screening indicates that the disruption of
the cell cycle (topotecan, bortezomib, nutlin-3), the genera-
tion of oxidative stress (DSF:Cu) or the inhibition of DNA
repair (olaparib) are mechanisms which may be exploited
to enhance the anti-tumour potency of 131I-MIP-1095. Fur-
ther investigation in vivo of the efficacy of radiosensitisers
in combination with 131I-MIP-1095 may expedite progress
of this therapeutic strategy for the clinical management of
metastatic PCa.
Figure 9 The effect of 1 lM AZD7762 on the c-radiation-induced
G2 arrest. The distribution of LNCaP cells throughout the cell cycle
was determined by fluorescence-activated cell sorting of propidium
iodide-stained cells 12 h following irradiation with 5 Gy in the pres-
ence of 1 lM AZD7762. One-way ANOVA with Bonferroni correction
was used to compare the mean percentage in G2-M. Data are
mean  SEM (n = 3), **P < 0.01, and ns indicates P > 0.05.
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